Language:

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

The New England journal of medicine, 2022-09, Vol.387 (11), p.978-988 [Peer Reviewed Journal]

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2209051 ;PMID: 36036525

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation
Author: Connolly, Stuart J. ; Karthikeyan, Ganesan ; Ntsekhe, Mpiko ; Haileamlak, Abraham ; El Sayed, Ahmed ; El Ghamrawy, Alaa ; Damasceno, Albertino ; Avezum, Alvaro ; Dans, Antonio M.L. ; Gitura, Bernard ; Hu, Dayi ; Kamanzi, Emmanuel R. ; Maklady, Fathi ; Fana, Golden ; Gonzalez-Hermosillo, J. Antonio ; Musuku, John ; Kazmi, Khawar ; Zühlke, Liesl ; Gondwe, Lillian ; Ma, Changsheng ; Paniagua, Maria ; Ogah, Okechukwu S. ; Molefe-Baikai, Onkabetse J. ; Lwabi, Peter ; Chillo, Pilly ; Sharma, Sanjib K. ; Cabral, Tantchou T.J. ; Tarhuni, Wadea M. ; Benz, Alexander ; van Eikels, Martin ; Krol, Amy ; Pattath, Divya ; Balasubramanian, Kumar ; Rangarajan, Sumathy ; Ramasundarahettige, Chinthanie ; Mayosi, Bongani ; Yusuf, Salim
Subjects: Allergy ; Anticoagulants ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Anticoagulation ; Arrhythmias ; Atrial fibrillation ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - etiology ; Autoimmune Disease ; Bacterial Infections ; Bleeding ; Blood clots ; Cardiac arrhythmia ; Cardiology ; Cardiovascular disease ; Cerebral infarction ; Clinical trials ; Comorbidity ; Coronary artery disease ; Creatinine ; Death ; Defibrillators ; Disease prevention ; Drug therapy ; Echocardiography ; Embolism ; Embolisms ; Factor Xa Inhibitors - adverse effects ; Factor Xa Inhibitors - therapeutic use ; Female ; Fibrillation ; Global Health ; Health aspects ; Heart attacks ; Heart diseases ; Hemorrhage - chemically induced ; Hemostasis ; Humans ; Immunology ; Infectious Disease ; Inflammatory Disease ; Low income groups ; Male ; Medical research ; Middle Aged ; Myocardial infarction ; Pacemakers ; Patient outcomes ; Patients ; Rheumatic heart disease ; Rheumatic Heart Disease - complications ; Rheumatic Heart Disease - diagnosis ; Rheumatic Heart Disease - diagnostic imaging ; Rheumatology ; Rivaroxaban ; Rivaroxaban - adverse effects ; Rivaroxaban - therapeutic use ; Stroke ; Stroke - etiology ; Stroke - prevention & control ; Survival ; Testing ; Thromboembolism ; Thrombosis ; Treatment Outcome ; Valvular Heart Disease ; Vitamin K ; Vitamin K - antagonists & inhibitors ; Warfarin - adverse effects ; Warfarin - therapeutic use
Is Part Of: The New England journal of medicine, 2022-09, Vol.387 (11), p.978-988
Description: Among patients with rheumatic heart disease and atrial fibrillation who received a vitamin K antagonist or rivaroxaban, the rate of stroke, systemic embolism, MI, or death from vascular or unknown causes was lower with a VKA, without increased bleeding.
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa2209051
PMID: 36036525
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

Copyright © 2022 Massachusetts Medical Society. All rights reserved. ;Copyright © 2022 Massachusetts Medical Society. ;COPYRIGHT 2022 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2209051 ;PMID: 36036525

Searching Remote Databases, Please Wait